Skip to main content
Top
Published in: Familial Cancer 3/2010

01-09-2010

Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families

Authors: Emily P. Slater, Peter Langer, Volker Fendrich, Nils Habbe, Brunhilde Chaloupka, Elvira Matthäi, Mercedes Sina, Stephan A. Hahn, Detlef K. Bartsch

Published in: Familial Cancer | Issue 3/2010

Login to get access

Abstract

Previous small scale studies reported that deleterious BRCA2 and CDKN2a germline mutations contribute to a subset of families with inherited pancreatic cancer. As the prevalence of those mutations in the setting of familial pancreatic cancer is still not well defined for the German population, we evaluated the presence of BRCA2 and CDKN2a germline mutations in a large cohort of familial pancreatic cancer (FPC) families from the German National Case Collection for Familial Pancreatic Cancer (FaPaCa). Fifty-six FPC families with at least two-first-degree relatives with confirmed pancreatic cancer that did not fulfill the criteria of other tumor predisposition syndromes, were analyzed for BRCA2 and CDKN2a germline mutations by DHPLC and/or direct sequencing. No deleterious CDKN2a mutations were identified in our families suggesting that CDKN2a mutations are unlikely to predispose PC in FPC families without melanoma. No deleterious BRCA2 mutations, but 6 unclassified variants, were detected in our FPC collection. Combining the prevalence of deleterious BRCA2 germline mutations from our previous separate study with the data from this study we were able to much more accurately estimate the BRCA2 carrier frequency for FPC families in the German population. A total of two mutations and 6 unclassified variants (mutation range: 2.8–11.4%) were thus identified in 70 German FPC families, indicating that the prevalence of BRCA2 mutations in the German FPC population is less frequent than previously reported.
Literature
1.
go back to reference Hruban RH, Petersen GM, Ha PK et al (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1–23PubMed Hruban RH, Petersen GM, Ha PK et al (1998) Genetics of pancreatic cancer. From genes to families. Surg Oncol Clin N Am 7:1–23PubMed
2.
go back to reference Applebaum SE, Kant JA, Whitcomb DC et al (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575–588CrossRefPubMed Applebaum SE, Kant JA, Whitcomb DC et al (2000) Genetic testing. Counseling, laboratory, and regulatory issues and the EUROPAC protocol for ethical research in multicenter studies of inherited pancreatic diseases. Med Clin North Am 84:575–588CrossRefPubMed
3.
go back to reference Bartsch DK, Sina-Frey M, Ziegler A et al (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516CrossRefPubMed Bartsch DK, Sina-Frey M, Ziegler A et al (2001) Update of familial pancreatic cancer in Germany. Pancreatology 1:510–516CrossRefPubMed
4.
go back to reference Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634–2638CrossRefPubMed Klein AP, Brune KA, Petersen GM et al (2004) Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 64:2634–2638CrossRefPubMed
5.
go back to reference McFaul CD, Greenhalf W, Earl J et al (2005) Anticipation in familial pancreatic cancer. Gut 55:252–258CrossRefPubMed McFaul CD, Greenhalf W, Earl J et al (2005) Anticipation in familial pancreatic cancer. Gut 55:252–258CrossRefPubMed
6.
7.
go back to reference Murphy KM, Brune KA, Griffin C et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793PubMed Murphy KM, Brune KA, Griffin C et al (2002) Evaluation of candidate genes MAP2K4, MADH4, ACVR1B and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res 62:3789–3793PubMed
8.
go back to reference Grützmann R, McFaul CD, Bartsch DK et al (2004) No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett 214:63–68CrossRefPubMed Grützmann R, McFaul CD, Bartsch DK et al (2004) No evidence for germline mutations of the LKB1/STK11 gene in familial pancreatic carcinoma. Cancer Lett 214:63–68CrossRefPubMed
9.
go back to reference Bartsch D, Fendrich V, Slater E et al (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117:718–722CrossRefPubMed Bartsch D, Fendrich V, Slater E et al (2005) RNASEL germline variants are associated with pancreatic cancer. Int J Cancer 117:718–722CrossRefPubMed
10.
go back to reference Bartsch DK, Krysewski K, Sina-Frey M et al (2006) Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 5(4):305–308CrossRefPubMed Bartsch DK, Krysewski K, Sina-Frey M et al (2006) Low frequency of CHEK2 mutations in familial pancreatic cancer. Fam Cancer 5(4):305–308CrossRefPubMed
11.
go back to reference Bartsch D, Sina-Frey M, Lang S et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730–737CrossRefPubMed Bartsch D, Sina-Frey M, Lang S et al (2002) CDKN2A germline mutations in familial pancreatic cancer. Ann Surg 236:730–737CrossRefPubMed
12.
go back to reference Lynch H, Brand R, Hogg D et al (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94:84–96CrossRefPubMed Lynch H, Brand R, Hogg D et al (2002) Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer 94:84–96CrossRefPubMed
13.
go back to reference Schutte M, da Costa LT, Hahn SA et al (1995) Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 92:5950–5954CrossRefPubMed Schutte M, da Costa LT, Hahn SA et al (1995) Identification by representational difference analysis of a homozygous deletion in pancreatic carcinoma that lies within the BRCA2 region. Proc Natl Acad Sci USA 92:5950–5954CrossRefPubMed
14.
go back to reference Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef Breast Cancer Linkage Consortium (1999) Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 91:1310–1316CrossRef
15.
go back to reference Gershoni-Baruch R, Patael Y, Dagan et al (2000) Association of the I1307 K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. Br J Cancer 83:153–155CrossRefPubMed Gershoni-Baruch R, Patael Y, Dagan et al (2000) Association of the I1307 K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. Br J Cancer 83:153–155CrossRefPubMed
16.
go back to reference Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360–5364PubMed Goggins M, Schutte M, Lu J et al (1996) Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res 56:5360–5364PubMed
17.
go back to reference Ozçelik H, Schmocker B, Di Nicola N et al (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16:17–18CrossRefPubMed Ozçelik H, Schmocker B, Di Nicola N et al (1997) Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet 16:17–18CrossRefPubMed
18.
go back to reference Hahn SA, Greenhalf W, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221CrossRefPubMed Hahn SA, Greenhalf W, Ellis I et al (2003) BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 95:214–221CrossRefPubMed
19.
go back to reference Martin ST, Matsubayashi H, Rogers CD et al (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24:3652–3656CrossRefPubMed Martin ST, Matsubayashi H, Rogers CD et al (2005) Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene 24:3652–3656CrossRefPubMed
20.
go back to reference Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:342–346CrossRefPubMed Couch FJ, Johnson MR, Rabe KG et al (2007) The prevalence of BRCA2 mutations in familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 16:342–346CrossRefPubMed
21.
go back to reference Gerdes B, Kress R, Rieder H et al (2002) Familial pancreatic cancer–concept for study of the National Case Collection and early diagnosis program for high risk people. Z Arztl Fortbild Qualitatssich 96:251–255PubMed Gerdes B, Kress R, Rieder H et al (2002) Familial pancreatic cancer–concept for study of the National Case Collection and early diagnosis program for high risk people. Z Arztl Fortbild Qualitatssich 96:251–255PubMed
22.
go back to reference Rieder H, Sina-Frey M, Ziegler A et al (2002) German national case collection of familial pancreatic cancer—clinical-genetic analysis of the first 21 families. Onkologie 25:262–266CrossRefPubMed Rieder H, Sina-Frey M, Ziegler A et al (2002) German national case collection of familial pancreatic cancer—clinical-genetic analysis of the first 21 families. Onkologie 25:262–266CrossRefPubMed
23.
go back to reference Brand RE, Lerch MM, Rubinstein WS et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469CrossRefPubMed Brand RE, Lerch MM, Rubinstein WS et al (2007) Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut 56:1460–1469CrossRefPubMed
24.
go back to reference Wagner T, Stoppa-Lyonnet D, Fleischmann E et al (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62:369–376CrossRefPubMed Wagner T, Stoppa-Lyonnet D, Fleischmann E et al (1999) Denaturing high-performance liquid chromatography detects reliably BRCA1 and BRCA2 mutations. Genomics 62:369–376CrossRefPubMed
25.
go back to reference Lynch HT, Kaurah P, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer. Cancer 112:2655–2663CrossRefPubMed Lynch HT, Kaurah P, Wirtzfeld D et al (2008) Hereditary diffuse gastric cancer. Cancer 112:2655–2663CrossRefPubMed
26.
go back to reference Langer P, Kann PH, Fendrich V et al (2009) 5 Years of prospective screening of high risk individuals from familial pancreatic cancer families. Gut 58:1410–1418CrossRefPubMed Langer P, Kann PH, Fendrich V et al (2009) 5 Years of prospective screening of high risk individuals from familial pancreatic cancer families. Gut 58:1410–1418CrossRefPubMed
27.
go back to reference Hu N, Wang C, Han XY et al (2004) Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene 23:852–858CrossRefPubMed Hu N, Wang C, Han XY et al (2004) Evaluation of BRCA2 in the genetic susceptibility of familial esophageal cancer. Oncogene 23:852–858CrossRefPubMed
28.
go back to reference Borg A, Sandberg T, Nilsson K et al (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260–1266CrossRefPubMed Borg A, Sandberg T, Nilsson K et al (2000) High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 92:1260–1266CrossRefPubMed
29.
go back to reference Goldstein A, Fraser M, Struewing J et al (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970–974CrossRefPubMed Goldstein A, Fraser M, Struewing J et al (1995) Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 333:970–974CrossRefPubMed
30.
go back to reference Rulyak S, Brentnall T, Lynch H et al (2003) Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 98:798–804CrossRefPubMed Rulyak S, Brentnall T, Lynch H et al (2003) Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome. Cancer 98:798–804CrossRefPubMed
31.
go back to reference Vasen H, Gruis N, Frants R et al (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809–811CrossRefPubMed Vasen H, Gruis N, Frants R et al (2000) Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 87:809–811CrossRefPubMed
32.
go back to reference Rozenblum E, Schutte M, Goggins M et al (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731–1734PubMed Rozenblum E, Schutte M, Goggins M et al (1997) Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 57:1731–1734PubMed
33.
go back to reference Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409–416PubMed Lal G, Liu G, Schmocker B et al (2000) Inherited predisposition to pancreatic adenocarcinoma: role of family history and germ-line p16, BRCA1, and BRCA2 mutations. Cancer Res 60:409–416PubMed
34.
go back to reference Pollock PM, Pearson JV, Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 15:77–88CrossRefPubMed Pollock PM, Pearson JV, Hayward NK (1996) Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer 15:77–88CrossRefPubMed
35.
go back to reference Ranade K, Hussussian CJ, Sikorski RS et al (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114–116CrossRefPubMed Ranade K, Hussussian CJ, Sikorski RS et al (1995) Mutations associated with familial melanoma impair p16INK4 function. Nat Genet 10:114–116CrossRefPubMed
36.
go back to reference Beristain E, Martíneuz-Bouzas C, Guerra I et al (2007) Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 106:255–262CrossRefPubMed Beristain E, Martíneuz-Bouzas C, Guerra I et al (2007) Differences in the frequency and distribution of BRCA1 and BRCA2 mutations in breast/ovarian cancer cases from the Basque country with respect to the Spanish population: implications for genetic counselling. Breast Cancer Res Treat 106:255–262CrossRefPubMed
37.
go back to reference Hahn SA, Schmiegel WH (1998) Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 59:493–501CrossRefPubMed Hahn SA, Schmiegel WH (1998) Recent discoveries in cancer genetics of exocrine pancreatic neoplasia. Digestion 59:493–501CrossRefPubMed
38.
go back to reference Lynch HT, Brand RE, Lynch JF et al (2000) Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 119:1756–1760CrossRefPubMed Lynch HT, Brand RE, Lynch JF et al (2000) Genetic counseling and testing for germline p16 mutations in two pancreatic cancer-prone families. Gastroenterology 119:1756–1760CrossRefPubMed
39.
go back to reference German Consortium for Hereditary Breast and Ovarian Cancer (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472–480CrossRef German Consortium for Hereditary Breast and Ovarian Cancer (2002) Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 97:472–480CrossRef
40.
go back to reference Brentnall TA, Bronner MP, Byrd DR et al (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247–255PubMed Brentnall TA, Bronner MP, Byrd DR et al (1999) Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 131:247–255PubMed
41.
go back to reference Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781CrossRefPubMed Canto MI, Goggins M, Hruban RH et al (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4:766–781CrossRefPubMed
42.
go back to reference van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515CrossRefPubMed van der Heijden MS, Brody JR, Dezentje DA et al (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515CrossRefPubMed
Metadata
Title
Prevalence of BRCA2 and CDKN2a mutations in German familial pancreatic cancer families
Authors
Emily P. Slater
Peter Langer
Volker Fendrich
Nils Habbe
Brunhilde Chaloupka
Elvira Matthäi
Mercedes Sina
Stephan A. Hahn
Detlef K. Bartsch
Publication date
01-09-2010
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 3/2010
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-010-9329-6

Other articles of this Issue 3/2010

Familial Cancer 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine